About US
Contact us
-
FiercePharmaPolitics—House passes Pelosi bill, Trump admin nixes biologics protections in trade pact and moreWelcome to theFiercePharmapolitical roundup, where each Monday we’ll highlight notable developments that could affect howdrugmakersoperate. As the year comes to an end, lawmakers and government offic2019/12/18
-
Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansionAmarin has been on a scorching run with its fish-oil derivative Vascepa after a major cardiovascular outcomes trial last year set a possible blockbuster trajectory for the drug. Now, the FDA has vote2019/12/17
-
Intercept's NASH decision delayed by FDA, but don't panic: analystsIntercept Pharmaceuticals has been gearing up for the potential launch of its nonalcoholic steatohepatitis (NASH) med, but now its waitlooks alittle longer. While the FDA was originally due to decide2019/12/17
-
ESMO I-O: BMS zooms in on squamous lung cancer patients as it dissects Opdivo-chemo combo failureGENEVA—As Bristol-Myers Squibb continues to search for bright spots in its eyebrow-raising Opdivo-chemo combo fail from June, it’s zeroing in on the population of squamous lung cancer patients who se2019/12/16
-
AstraZeneca rounds out stellar China year—and beats Roche to the punch—with Imfinzi lung cancer nodAstraZeneca’s oncology business has chalked up several wins in China this year. Now, the British drugmaker has another important one to brag about. China’s National Medical Products Administrationapp2019/12/16
-
ESMO I-O: Keytruda shines among KRAS-mutated patients in Merck's latest lung cancer analysisGENEVA—With all the buzz about KRAS these days, Merck’s been fielding its fair share of questions about whether lung cancer patients with KRAS mutations respond as well to Keytruda as other previousl2019/12/13
-
SABCS: Merck's Keytruda notches win in triple-negative breast cancer as Roche's Tecentriq falls shortSAN ANTONIO—Merck & Co.'s Keytruda and Roche's Tecentriq are battlingfor immuno-oncology supremacy in an ever-growing range of indications. But in hard-to-treat triple-negative breast cancer (TNB2019/12/13
-
Bayer's $7.6B bid to offload animal health to Elanco draws extra FTC antitrust attentionBayer’s eager to send its animal health unit toElancoso it can focus its healthcare efforts on pharmaceuticals. But that $7.6 billion selloff, like many other recent life sciences deals, has hit an a2019/12/12
-
How will Sanofi save €2B? Chopping support staff and 'smart' purchasing, for 2Like many a corporate rejuvenation plan, CEO Paul Hudson's blueprint for Sanofi includes some hefty cost cutting. The French drugmaker's aiming for €2 billion in annual savings by 2022, executives sa2019/12/12
-
Sanofi, Regeneron uncouple on long-standing drug partnership, splitting up Praluent, KevzaraAfter more than a decade of working together, Sanofi and Regeneron's drug partnership finally turned a profit recentlyon the back of strong sales of blockbuster Dupixent. Instead of staying the cours2019/12/11